Onconetix, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ONCO Nasdaq 2830 www.onconetix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Onconetix, Inc.

Onconetix announces financing through private placement, debt settlement - Sep 27th, 2025 6:40 am
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - Sep 26th, 2025 6:30 am
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - Sep 26th, 2025 6:15 am
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - Sep 22nd, 2025 6:00 am
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - Jul 16th, 2025 6:17 am
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - Jun 16th, 2025 6:22 am
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - Jun 11th, 2025 9:30 am
Onconetix receives additional delisting notice from Nasdaq - May 23rd, 2025 3:00 pm
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - May 22nd, 2025 2:50 pm
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - Apr 8th, 2025 6:30 am
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Mar 25th, 2025 6:50 am
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - Mar 24th, 2025 6:45 am
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - Mar 19th, 2025 6:00 am
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - Dec 12th, 2024 3:00 pm